CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
LY2216684 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01380691
NCT01380691Phase 1Completed
CompareCT.gov

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction of LY2216684 With Alcohol in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jun 27, 2011·Updated Jun 26, 2019

In Brief

A Phase 1 clinical trial evaluating LY2216684, Placebo-matching LY2216684, and 2 other interventions for Major Depressive Disorder. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 27, 2011
Enrollment StartJun 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.0 years ago

Interventions

LY2216684drug

Administered orally

Placebo-matching LY2216684drug

Administered orally

Placebo-matching alcoholic beveragedrug

Administered orally

Alcoholic beveragedrug

Administered orally